Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Update

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 22,000 shares, a growth of 349.0% from the February 13th total of 4,900 shares. Based on an average daily trading volume, of 63,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the shares of the stock are short sold.

Institutional Investors Weigh In On Estrella Immunopharma

A hedge fund recently raised its stake in Estrella Immunopharma stock. Geode Capital Management LLC grew its position in Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 93,418 shares of the company’s stock after buying an additional 16,862 shares during the period. Geode Capital Management LLC owned 0.26% of Estrella Immunopharma worth $106,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.35% of the company’s stock.

Estrella Immunopharma Trading Up 5.3 %

NASDAQ:ESLA traded up $0.05 during trading hours on Wednesday, hitting $1.02. The company had a trading volume of 22,683 shares, compared to its average volume of 78,798. Estrella Immunopharma has a 1 year low of $0.63 and a 1 year high of $3.23. The company has a 50-day moving average of $1.14 and a 200 day moving average of $1.07. The company has a market cap of $36.90 million, a P/E ratio of -3.92 and a beta of 0.40.

Analyst Ratings Changes

Separately, D. Boral Capital initiated coverage on shares of Estrella Immunopharma in a research report on Tuesday, February 18th. They set a “buy” rating and a $16.00 price target on the stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.